NCT01612429View on ClinicalTrials.gov

Carbamylation in Renal Disease-modulation With Amino Acid Therapy

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
End Stage Renal Failure on Dialysis
Interventions
DIETARY_SUPPLEMENT

Amino acid supplementation

Single arm study in which dialysis patients will receive up to 500 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing 26.8 grams of essential amino acids at 125 mL/h during each dialysis session (3 times weekly for 6 weeks)

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01612429 - Carbamylation in Renal Disease-modulation With Amino Acid Therapy | Biotech Hunter | Biotech Hunter